TITLE

Molecule of the Month

AUTHOR(S)
Bolinger, Julie D.; Lindsley, Craig W.
PUB. DATE
August 2007
SOURCE
Current Topics in Medicinal Chemistry;Aug2007, Vol. 7 Issue 16, p1643
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The most prescribed and top selling drugs of 2006: generics, biologics and, of course, Lipitor�. In the spring of 2007, data for the top 200 prescription drugs, in terms of both sales and number of dispensed prescriptions, was released [1-3]. Total sales of prescription drugs reached $275 billion in 2006, an impressive 8.3% increase from 2005; in contrast, sales only increased 5.3% over 2004. The number of dispensed prescriptions also increased in 2006 to 3.7 million (a 4.6% increase from 2005) [1-3]. These data are very encouraging for the pharmaceutical industry, especially considering that 2006 witnessed the loss of patent protection for blockbusters Zocor�, Zoloft�, Plavix�, Provochol� and Mobic� which fell victim to generic competition. In fact, the overriding theme of the 2006 was a significant increase in generic prescriptions and sales. While many factors play a role, the 8.3% increase in sales is primarily due to the successful launch of the full Medicare Part D benefit which extended prescription drug coverage benefits to US citizens that historically had little to no coverage. Medicare Part D encompasses every major class of pharmaceuticals and, in 2006, 63% of all prescriptions dispensed to Medicare Part D beneficiaries were generic products [1-3]...
ACCESSION #
27238994

 

Related Articles

  • Sign of Things to Come? Houlton, Sarah // Pharmaceutical Executive;Feb2006, Vol. 26 Issue 2, p50 

    The article reports that the European Medicines Agency (EMEA) intends to complete its guidelines for the approval of generic copies of biologic medicines in early 2006. The approval of biogenerics could be a potential business opportunity for generic companies. The initial guidelines are...

  • Demystifying generics.  // Consumer Reports on Health;Aug2012, Vol. 24 Issue 8, p9 

    The article presents an interview with pharmaceutical scientist Vinod P. Shah. He describes the U.S. Food and Drug Administration (FDA) approval requirements for generic drugs, discusses the effects of generic drugs with a narrow therapeutic index (NTI) on certain patients, and notes the...

  • Education and promotion of generics might put the brakes on pharm costs. Nozar, Robert A. // Managed Healthcare Executive;Feb2002, Vol. 12 Issue 2, p36 

    Assesses the importance of generic drugs for pharmaceutical companies in the U.S. Development of prescription drugs; Success of Generic First program by Blue Cross Blue Shield of Michigan; Use of generic brand of drug for consumers.

  • Drugmakers readying for slew of drugs going off patent. Rosendahl, Iris // Drug Topics;8/21/95 Generics Supplement, Vol. 139 Issue 16, p44S 

    Discusses the implications for the generic drug industry of the patent or exclusivity expiration of over 150 major branded pharmaceutical products between 1995 and 2004. Products whose patents have expired but still have no generic competition; Opportunity for the generic industry to gain...

  • Strategic alliances: Less risky than marriage. Glaser, Martha // Drug Topics;11/20/95 Generics, Vol. 139 Issue 22, p8S 

    Discusses the trend in strategic alliances among companies in the generic drug industry. Advantage of a strategic alliance over a merger; Generic market's potential; Justification for the arrangements.

  • How independent generic manufacturers will thrive. Muirhead, Greg // Drug Topics;11/20/95 Generics, Vol. 139 Issue 22, p26S 

    Discusses the outlook for independent generic drug manufacturers. Number of companies that would remain independent; Alliances in the industry; Strategies for independent companies.

  • Germany Generics.  // Generics Industry Profile: Germany;2002, pN.PAG 

    Presents a profile of the generics industry in Germany. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry;...

  • Japan Generics.  // Generics Industry Profile: Japan;2002, pN.PAG 

    Presents a profile of the generics industry in Japan. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry;...

  • Spain Generics.  // Generics Industry Profile: Spain;2002, pN.PAG 

    Presents a profile of the generics industry in Spain. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the industry;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics